12 completed, 6 unknown, 2 recruiting, 1 not yet recruiting. 4 Not applicable, 4 Phase 2, 4 Phase 4, 3 Phase 1, 1 Early Phase 1.
Follow Cholinergic Antagonists: new trials by email Literature Review of Cholinergic Antagonists trials Research Report on Cholinergic Antagonists
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Parasacral TENS Project Parasacral transcutaneous electric nerve stimulation (TENS), Oxybutynin - Overactive Bladder (OAB), Lower Urinary Tract Dysfunction | Not applicable | Not yet recruiting | University of Virginia | 60 | 2026-09-30 | 2026-10-23 |
| Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE Mirabegron (beta3-adrenoceptor agonist), Anticholinergics, Desmopressin (DDAVP) - Nocturnal Enuresis in Children | Phase 3 | Recruiting | Mansoura University | 120 | 2024-12-01 | 2025-09-30 |
| Outcomes of Proactive Management of Children With Myelomeningocele CIC, Anticholinergic - Urologic Diseases | Unknown | Assiut University | 40 | 2024-03-04 | 2024-03-08 | |
| Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children Beta3-Agonists, Adrenergic, Anticholinergic drug, Solifenacin - Voiding Disorders, Overactive Bladder | Phase 1 / Phase 2 | Unknown | Mansoura University | 70 | 2022-02-01 | 2022-02-15 |
| Cholinergic Health After Menopause (CHAMP) Cholinergic antagonist - Postmenopausal Symptoms, Aging | Early Phase 1 | Completed | University of Vermont | 98 | 2020-03-15 | 2026-06-12 |
| Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI) - Overactive Bladder, Dementia | Phase 4 | Completed | Baylor Research Institute | 12 | 2019-08-05 | 2024-02-02 |
| Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis. Dextromethorphan 15 milligrams, Ipratropium Bromide 20Micrograms Inhaler, Honey 30 g (full tablespoon) - Acute Bronchitis | Phase 4 | Completed | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | 668 | 2019-02-01 | 2022-08-30 |
| Sexual Function Trial of Overactive Bladder: Medication Versus PTNS Anticholinergic, PTNS - Female Sexual Dysfunction, Overactive Bladder | Completed | Medstar Health Research Institute | 175 | 2017-01-30 | 2020-08-18 | |
| Orphenadrine and Methocarbamol for LBP Orphenadrine, Methocarbamol, Naproxen - Low Back Pain | Phase 4 | Completed | Montefiore Medical Center | 240 | 2016-03-01 | 2018-06-26 |
| Effect of Mirabegron on Bladder Compliance Mirabegron (beta3-adrenoceptor agonist), Anticholinergics - Patients With Low Bladder Compliance of 20ml/H2O or Less Despite Taking Anticholinergics | Not applicable | Unknown | Yonsei University | 15 | 2016-01-12 | 2023-02-27 |
| Trigonal vs Non Trigonal Botox Injection in OAB. botulinum toxin A - Urologic Diseases, Overactive Bladder Syndrome | Not applicable | Completed | Mansoura University | 80 | 2015-06-14 | 2018-10-09 |
| The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar. Oxybutynin, Placebos - Hyperhidrosis | Not applicable | Completed | Tel-Aviv Sourasky Medical Center | 61 | 2015-05-01 | 2016-11-25 |
| 24hr Effects of Tiotropium Bromide in Tetraplegia Tiotropium Bromide, Placebo - Spinal Cord Injury | Phase 2 | Completed | James J. Peters Veterans Affairs Medical Center | 10 | 2014-07-01 | 2020-09-16 |
| Treatment Outcomes Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction First line treatment: oral NSAID and anticholinergic agents, Second line treatment: additional treatment for pain control, Third line treatment: A course of intravesical hyaluronate will be given. - Voiding Dysfunction, Substance Abuse | Recruiting | Chinese University of Hong Kong | 1500 | 2011-12-10 | 2026-10-28 | |
| Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC), Anticholinergics (AC) - Pulmonary Disease, Chronic Obstructive | Completed | GlaxoSmithKline | 2849 | 2011-03-01 | 2017-05-16 | |
| Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers. Darifenacin - Bioequivalency | Phase 1 | Unknown | Center for Clinical Pharmacology Research Bdbeq S.A. | 24 | 2010-12-01 | 2010-10-27 |
| Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers. Darifenacin - Bioequivalency | Phase 1 | Unknown | Center for Clinical Pharmacology Research Bdbeq S.A. | 24 | 2010-11-01 | 2010-10-25 |
| Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population fluticasone propionate/salmeterol xinafoate, Anticholinergics - Pulmonary Disease, Chronic Obstructive | Completed | GlaxoSmithKline | 1 | 2010-10-01 | 2017-05-30 | |
| Ability to Awaken in Nonmonosymptomatic Enuresis anticholinergic - Enuresis, Nocturnal, 2 (Disorder) | Completed | Seoul National University Hospital | 119 | 2010-07-01 | 2016-07-28 | |
| A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis Oxybutynin 5 mg pills - Hyperhidrosis | Phase 2 | Completed | Federal University of São Paulo | 32 | 2010-03-01 | 2011-04-04 |
Showing 20 of 22. Sign in to see all of them.
Urinary Bladder, Overactive (4) · Hyperhidrosis (2) · Pulmonary Disease, Chronic Obstructive (2) · Urologic Diseases (2) · Akathisia, Drug-Induced (1) · Alzheimer Disease (1) · Anticholinergic Syndrome (1) · Bronchitis (1) · Cough (1) · Dementia (1) · Enuresis (1) · Low Back Pain (1) · Lower Urinary Tract Symptoms (1) · Meningomyelocele (1) · Movement Disorders (1)
Mansoura University (3) · Center for Clinical Pharmacology Research Bdbeq S.A. (2) · GlaxoSmithKline (2) · Ajou University School of Medicine (1) · Assiut University (1) · Baylor Research Institute (1) · Chinese University of Hong Kong (1) · Federal University of São Paulo (1) · Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina (1) · James J. Peters Veterans Affairs Medical Center (1) · Medstar Health Research Institute (1) · Merck Sharp & Dohme LLC (1) · Montefiore Medical Center (1) · Seoul National University Hospital (1) · Tel-Aviv Sourasky Medical Center (1)
United States (5) · Egypt (2) · South Korea (2) · Uruguay (2) · Hong Kong (1) · Spain (1)
Francisco E. Estevez-Carrizo, MD (2) · Susana Parrillo, M.D. (2) · Ahmad Elderwy, prof (1) · Ahmed Shoma, MD (1) · Altair S Costa Jr, MD (1) · Ana Moragas, MD PhD (1) · Benjamin W Friedman, MD, MS (1) · Gregory Schilero, MD (1) · Islam Mansour, Mb ChB (1) · Jang Hwan Kim (1) · Jill Danford, MD (1) · Julie A Dumas, Ph.D. (1) · Kee Myung Lee, M.D., Ph.D. (1) · Kwanjin PArk, Pf. (1)
PMID 10569435, PMID 15663976, PMID 19233423, PMID 20626389, PMID 21963104, PMID 22341836, PMID 23167161, PMID 24519200, PMID 26114588, PMID 29089169, PMID 31101700, PMID 31723443, PMID 36239199, PMID 37160401, PMID 7630654, PMID 8337005